Log in
Lost password
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NATIONAL STOCK EXCHANGE OF INDIA  >  Ranbaxy Laboratories Limited    RANBAXY   INE015A01028

News SummaryMost relevantAll newsSector news 

Ranbaxy Resumes Generic Lipitor Production for U.S.

02/22/2013 | 12:05pm US/Eastern

Ranbaxy Laboratories Ltd. (500359.BY) said Friday it has resumed manufacturing generic copies of the cholesterol-lowering drug Lipitor for the U.S. market, following a production suspension late last year after tiny glass particles were found in the product.

Ranbaxy voluntarily recalled about 480,000 bottles of generic Lipitor, also known as atorvastatin calcium, in the U.S. in November, after discovering the glass fragment problem.

An Indian unit of Japan's Daiichi Sankyo Co. (DSNKY, 4568.TO), Ranbaxy said Friday it's working with the U.S. Food and Drug Administration as it implements corrective actions designed to prevent future manufacturing problems.

Ranbaxy has commenced production of the drug substance for its atorvastatin product, as part of the first step toward resuming supplies to the U.S. market, the company said in a statement.

The recall didn't affect Ranbaxy's generic Lipitor product outside the U.S.

In January, Ranbaxy said it completed an investigation of the manufacturing problem that caused the glass particles to turn up in the product. The company previously said it suspected that a faulty tank at a facility in India caused the problem.

Ranbaxy was one of the biggest sellers of generic Lipitor in the U.S. after Pfizer Inc. (>> Pfizer Inc.) lost exclusivity for the branded product in late 2011.

But Ranbaxy's share of the generic Lipitor market has plunged to 2% from about 45% before the recall, according to J.P. Morgan, which cited data from IMS Health. Other generic companies including Mylan Inc. (>> Mylan Inc.) and Apotex Inc. have gained share of the generic Lipitor market.

Write to Peter Loftus at peter.loftus@dowjones.com

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

Stocks mentioned in the article : Mylan Inc., Pfizer Inc.
React to this article
06/28 Indian pharma's struggle to tighten standards paves way for M&A deals
04/27 DAIICHI SANKYO : India exit, a Credit Positive
04/26 DAIICHI SANKYO : Sun pharma: long-term portfolio therapy
04/22 Daiichi salvages $3.2 bn from sunk Ranbaxy investment
04/21 Daiichi Sankyo to Sell Shares of Sun Pharma
04/21 Daiichi to sell stake worth ` 22k cr in Sun Pharma
04/21 Daiichi Sankyo Exits Sun Pharma
04/21 Sun Pharma exit may net Daiichi $3.6bn
04/20 Daiichi sankyo to sell stake in sun pharma
04/20DJDaiichi Sankyo to Sell Sun Pharma Stake
Income Statement Evolution
More Financials